BioCryst Pharmaceuticals, Inc.
BCRX
$8.39
-$0.17-1.99%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 557.51M | 503.49M | 450.71M | 412.58M | 382.24M |
| Total Other Revenue | -- | 1.04M | 4.94M | 7.46M | 8.51M |
| Total Revenue | 557.51M | 503.49M | 450.71M | 412.58M | 382.24M |
| Cost of Revenue | 187.90M | 181.04M | 186.96M | 198.50M | 202.21M |
| Gross Profit | 369.60M | 322.44M | 263.75M | 214.08M | 180.03M |
| SG&A Expenses | 315.41M | 289.27M | 266.29M | 249.85M | 235.42M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 503.31M | 470.31M | 453.26M | 448.36M | 437.63M |
| Operating Income | 54.20M | 33.17M | -2.54M | -35.78M | -55.39M |
| Income Before Tax | -32.19M | -51.18M | -86.95M | -124.13M | -146.50M |
| Income Tax Expenses | 3.52M | 2.29M | 1.93M | -308.00K | -564.00K |
| Earnings from Continuing Operations | -35.71 | -53.47 | -88.88 | -123.82 | -145.93 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.71M | -53.47M | -88.88M | -123.82M | -145.93M |
| EBIT | 54.20M | 33.17M | -2.54M | -35.78M | -55.39M |
| EBITDA | 57.24M | 36.21M | 469.00K | -33.21M | -52.71M |
| EPS Basic | -0.17 | -0.26 | -0.43 | -0.61 | -0.73 |
| Normalized Basic EPS | -0.08 | -0.15 | -0.26 | -0.37 | -0.44 |
| EPS Diluted | -0.18 | -0.26 | -0.43 | -0.61 | -0.73 |
| Normalized Diluted EPS | -0.09 | -0.15 | -0.26 | -0.37 | -0.44 |
| Average Basic Shares Outstanding | 832.69M | 829.59M | 826.78M | 820.80M | 803.54M |
| Average Diluted Shares Outstanding | 849.43M | 835.97M | 826.78M | 820.80M | 803.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |